- Home
- QURE vs ABCL Comparison
QURE vs ABCL Comparison
Compare QURE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- ABCL
- Stock Information
- Founded
- QURE 1998
- ABCL 2012
- Country
- QURE Netherlands
- ABCL Canada
- Employees
- QURE N/A
- ABCL N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- ABCL Health Care
- Exchange
- QURE Nasdaq
- ABCL Nasdaq
- Market Cap
- QURE 725.4M
- ABCL 772.9M
- IPO Year
- QURE 2007
- ABCL 2020
- Fundamental
- Price
- QURE $14.24
- ABCL $3.45
- Analyst Decision
- QURE Strong Buy
- ABCL Strong Buy
- Analyst Count
- QURE 10
- ABCL 4
- Target Price
- QURE $37.20
- ABCL $8.33
- AVG Volume (30 Days)
- QURE 1.3M
- ABCL 7.5M
- Earning Date
- QURE 07-31-2025
- ABCL 08-05-2025
- Dividend Yield
- QURE N/A
- ABCL N/A
- EPS Growth
- QURE N/A
- ABCL N/A
- EPS
- QURE N/A
- ABCL N/A
- Revenue
- QURE $20,201,000.00
- ABCL $23,114,000.00
- Revenue This Year
- QURE N/A
- ABCL N/A
- Revenue Next Year
- QURE $278.91
- ABCL $67.99
- P/E Ratio
- QURE N/A
- ABCL N/A
- Revenue Growth
- QURE 6.30
- ABCL N/A
- 52 Week Low
- QURE $3.73
- ABCL $1.89
- 52 Week High
- QURE $19.18
- ABCL $4.09
- Technical
- Relative Strength Index (RSI)
- QURE 45.40
- ABCL 71.02
- Support Level
- QURE $13.65
- ABCL $3.52
- Resistance Level
- QURE $15.35
- ABCL $4.09
- Average True Range (ATR)
- QURE 0.90
- ABCL 0.31
- MACD
- QURE -0.28
- ABCL 0.04
- Stochastic Oscillator
- QURE 14.68
- ABCL 70.43
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.